+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cell & Gene Therapy Drug Delivery Devices Market by Device Type, End User, Product Type, Therapy Type, Distribution Channel - Global Forecast to 2030- Product Image
Cell & Gene Therapy Drug Delivery Devices Market by Device Type, End User, Product Type, Therapy Type, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Cell & Gene Therapy Drug Delivery Devices Market by Device Type, End User, Product Type, Therapy Type, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011242
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cell & Gene Therapy Drug Delivery Devices Market grew from USD 1.17 billion in 2024 to USD 1.29 billion in 2025. It is expected to continue growing at a CAGR of 10.03%, reaching USD 2.08 billion by 2030.

Setting the Stage for Cell and Gene Therapy Delivery Innovations

Cell and gene therapy represent a paradigm shift in modern medicine, offering the promise of curative treatments for once-intractable conditions. This executive summary provides a concise yet comprehensive overview of the delivery devices enabling these therapies, spotlighting the technological advances, adoption drivers, and emerging challenges that define the current landscape. By synthesizing the most pertinent developments, readers will gain clarity on the critical innovations shaping patient care and the strategic imperatives that will guide industry decision-making in the years ahead.

As the market evolves, stakeholders-from device manufacturers to healthcare providers-must navigate a complex interplay of regulatory, economic, and clinical factors. This introduction sets the stage for a deeper examination of transformative shifts, tariff impacts, segmentation nuances, regional dynamics, competitive intelligence, and actionable recommendations. In doing so, it lays the groundwork for a holistic understanding of how delivery devices will underpin the next generation of cell and gene therapy breakthroughs.

Emerging Dynamics Reshaping the Therapy Device Landscape

The device landscape for cell and gene therapies is undergoing profound transformation driven by technological convergence and evolving patient expectations. Advanced microfluidic platforms are delivering unprecedented precision in handling delicate biologics, while next-generation autoinjectors and needle-free injectors emphasize ease of use and adherence in self-administration settings. Concurrently, artificial intelligence and digital health integrations are optimizing dose accuracy, monitoring patient outcomes in real time, and enabling remote therapy management.

Regulatory harmonization efforts are reducing approval timelines and fostering cross-border collaboration, while cost-containment pressures push for scalable, cost-effective manufacturing solutions. At the same time, sustainability considerations are driving demand for reusable components and eco-friendly materials. Together, these forces are redefining competitive benchmarks and prompting device developers to innovate in areas such as ergonomic design, modularity, and value-added digital ecosystems. The net effect is a rapidly shifting market environment where agility and foresight determine winners and laggards alike.

Assessing the Ripple Effects of US Tariffs on Device Supply Chains

The introduction of new United States tariffs in 2025 has reverberated across device supply chains, particularly affecting the import of critical polymers, sensors, and electronic components. Manufacturers are contending with elevated input costs, prompting strategic re-evaluations of sourcing, with some shifting assembly operations to tariff-exempt jurisdictions and others renegotiating supplier contracts to mitigate margin erosion.

These cost pressures are compounded by elongated lead times and inventory challenges, forcing procurement teams to adopt more robust demand forecasting and diversified sourcing strategies. Downstream, healthcare providers face potential pricing adjustments that could influence therapy adoption rates and reimbursement negotiations. In response, leading device companies are accelerating investments in domestic manufacturing capabilities, pursuing localized partnerships, and exploring tariff-avoidance mechanisms to sustain competitive pricing and ensure uninterrupted supply to critical treatment centers.

Deconstructing Market Segments to Reveal Hidden Growth Drivers

A detailed examination of device type segmentation reveals a diverse array of delivery mechanisms, each addressing unique clinical and patient requirements. Autoinjectors have gained traction for their familiar form factor and user-friendly operation, while implantable and infusion pumps offer controlled, continuous administration suited for chronic or high-dose therapies. Microfluidic devices stand out for their precision handling of sensitive cell suspensions, whereas needle-free injectors and pre-filled syringes cater to rapid, painless delivery in outpatient or home settings. Conventional syringes remain relevant in controlled environments where simplicity and cost-efficiency are paramount.

End user segmentation underscores distinct channels of care delivery. Clinics and specialty centers benefit from compact, versatile devices optimized for varied therapeutic protocols, whereas hospitals leverage high-throughput systems capable of accommodating complex infusion regimens. Homecare adoption is rising as patient-centric models empower self-administration, highlighting the need for intuitive, fail-safe designs that support nonclinical caregivers.

In terms of product type, reusable platforms are favored for therapies requiring repeated dosing or long-term treatment cycles, offering cost amortization and reduced waste generation. Single-use disposables, in contrast, address sterility concerns and streamline workflow in high-risk or acute scenarios.

Therapy type further refines the market landscape. Within cell therapy, CAR-T products demand closed-system pumps to maintain sterility and cell viability, dendritic cell protocols rely on precise low-volume administration, and stem cell applications necessitate devices capable of gentle handling. Gene therapy mobilizes viral and non-viral vectors, each imposing distinct formulation and delivery requirements that shape device specifications and validation pathways.

Distribution channel analysis highlights the pivotal role of hospital pharmacies in managing high-value therapies under rigorous cold-chain controls. Online pharmacy channels, spanning mail-order and traditional e-commerce, are emerging as convenient conduits for stable formulations and ancillary supplies, while retail pharmacies-both chain and independent-are carving out roles in supporting outpatient treatment adherence through pick-up and counseling services.

Regional Nuances Influencing Device Adoption and Growth

Regional market characteristics reveal divergent growth trajectories and strategic priorities. In the Americas, robust reimbursement frameworks and established commercial infrastructures underpin rapid adoption of innovative delivery devices. The presence of leading biopharmaceutical hubs accelerates clinical partnerships and pilot deployments, fostering a fertile environment for first-mover device introductions.

Meanwhile, the Europe, Middle East and Africa region exhibits a heterogeneous mosaic of regulatory pathways and healthcare funding models. Western European markets often demand rigorous clinical evidence and cost-utility analyses, whereas emerging Middle East and African markets prioritize access programs and public-private collaborations to support infrastructure development and local manufacturing initiatives.

Asia-Pacific stands out for its dynamic patient populations and aggressive government initiatives to bolster biomanufacturing capacity. China, Japan, and South Korea are channeling significant investments into advanced therapy guidelines and domestic device certification processes, while Southeast Asian countries focus on leveraging digital health platforms to expand homecare and remote monitoring capabilities. Collectively, these regional dynamics shape global device strategies and inform localized go-to-market approaches.

Competitive Landscape Spotlight on Leading Device Innovators

The competitive arena features a blend of established medical device manufacturers and agile biotechnology firms, each vying to define next-generation delivery standards. Industry frontrunners allocate substantial resources to proprietary platform development, leveraging deep portfolios of patents to secure technology leadership. Collaborative ventures and strategic alliances with contract development and manufacturing organizations are common, enabling accelerated scale-up and distribution reach.

Emerging players differentiate through niche specialization, targeting high-value segments such as microfluidics for cell therapy or advanced autoinjector ergonomics for home infusion. These innovators often rely on venture capital infusion and academic partnerships to advance proof-of-concept prototypes into regulatory-approved commercial products. Across the board, competitive advantage hinges on balancing R&D intensity with streamlined manufacturing processes and tailored customer support models that enhance therapy adherence and outcomes.

Strategic Imperatives to Navigate Future Market Challenges

To navigate the complex environment, industry leaders must prioritize scalable manufacturing platforms that accommodate both autoinjectors and precision infusion technologies while maintaining cost discipline. Leveraging modular, adaptable production lines will enable rapid response to shifting demand and tariff fluctuations. At the same time, integrating digital health functionalities-such as dose tracking apps and remote monitoring dashboards-will deepen stakeholder engagement and generate real-world evidence to support reimbursement negotiations.

Robust supply chain diversification is essential. Establishing dual sourcing agreements for critical components and deploying real-time analytics for inventory optimization will mitigate disruptions. Proactive regulatory engagement, including participation in harmonization working groups, will smooth approval pathways and reinforce commercial readiness across regions. Finally, pursuing value-based partnerships with healthcare providers and payers will align device innovation with clinical and economic outcomes, fostering long-term adoption and market sustainability.

Rigorous Multi-Method Approach Underpinning the Analysis

This analysis is grounded in a multi-method research design that combines extensive secondary research with primary qualitative interviews across device manufacturers, clinical experts, and payers. Proprietary databases were mined to extract key market intelligence, while regulatory filings and patent registries provided insight into innovation trajectories. Triangulation of data points ensured validity, supplemented by scenario modeling to test potential policy and tariff impacts.

Expert consultations informed segmentation frameworks, ensuring that device functionality, end-user requirements, and distribution channels were accurately captured. Peer review by industry analysts and cross-validation against real-world case studies reinforced the credibility of findings. This rigorous methodology underpins the strategic insights and actionable recommendations presented in this report, offering stakeholders a robust foundation for investment and partnership decisions.

Summarizing Insights and Charting the Path Forward

In summary, the cell and gene therapy delivery device market is at an inflection point where technological innovation, regulatory evolution, and economic pressures converge. Distinct segmentation insights reveal pockets of high growth potential, while regional dynamics underscore the importance of tailored market entry strategies. The impact of newly introduced tariffs necessitates supply chain resilience and cost mitigation measures, and competitive positioning will hinge on digital integration and strategic collaborations.

As industry participants chart their course forward, the recommendations outlined herein provide a clear roadmap for sustaining momentum and capturing emerging opportunities. By aligning device innovation with clinical needs, optimizing manufacturing agility, and engaging proactively with regulatory and reimbursement stakeholders, organizations can secure a leadership position in this transformative market.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Device Type
    • Autoinjector
    • Implantable Pump
    • Infusion Pump
    • Microfluidic Device
    • Needle-Free Injector
    • Pre-Filled Syringe
    • Syringe
  • End User
    • Clinic
    • Homecare
    • Hospital
    • Specialty Center
  • Product Type
    • Reusable
    • Single Use
  • Therapy Type
    • Cell Therapy
      • CAR-T Therapy
      • Dendritic Cell Therapy
      • Stem Cell Therapy
    • Gene Therapy
      • Non-Viral Vector
      • Viral Vector
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
      • Mail Order Pharmacy
      • Traditional Online Pharmacy
    • Retail Pharmacy
      • Chain Pharmacy
      • Independent Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Becton, Dickinson and Company
  • Terumo Corporation
  • B. Braun Melsungen AG
  • ICU Medical, Inc.
  • West Pharmaceutical Services, Inc.
  • Gerresheimer AG
  • Ypsomed Holding AG
  • Catalent, Inc.
  • Fresenius SE & Co. KGaA
  • MaxCyte, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cell & Gene Therapy Drug Delivery Devices Market, by Device Type
8.1. Introduction
8.2. Autoinjector
8.3. Implantable Pump
8.4. Infusion Pump
8.5. Microfluidic Device
8.6. Needle-Free Injector
8.7. Pre-Filled Syringe
8.8. Syringe
9. Cell & Gene Therapy Drug Delivery Devices Market, by End User
9.1. Introduction
9.2. Clinic
9.3. Homecare
9.4. Hospital
9.5. Specialty Center
10. Cell & Gene Therapy Drug Delivery Devices Market, by Product Type
10.1. Introduction
10.2. Reusable
10.3. Single Use
11. Cell & Gene Therapy Drug Delivery Devices Market, by Therapy Type
11.1. Introduction
11.2. Cell Therapy
11.2.1. CAR-T Therapy
11.2.2. Dendritic Cell Therapy
11.2.3. Stem Cell Therapy
11.3. Gene Therapy
11.3.1. Non-Viral Vector
11.3.2. Viral Vector
12. Cell & Gene Therapy Drug Delivery Devices Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.3.1. Mail Order Pharmacy
12.3.2. Traditional Online Pharmacy
12.4. Retail Pharmacy
12.4.1. Chain Pharmacy
12.4.2. Independent Pharmacy
13. Americas Cell & Gene Therapy Drug Delivery Devices Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Cell & Gene Therapy Drug Delivery Devices Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Cell & Gene Therapy Drug Delivery Devices Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Becton, Dickinson and Company
16.3.2. Terumo Corporation
16.3.3. B. Braun Melsungen AG
16.3.4. ICU Medical, Inc.
16.3.5. West Pharmaceutical Services, Inc.
16.3.6. Gerresheimer AG
16.3.7. Ypsomed Holding AG
16.3.8. Catalent, Inc.
16.3.9. Fresenius SE & Co. KGaA
16.3.10. MaxCyte, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET MULTI-CURRENCY
FIGURE 2. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET MULTI-LANGUAGE
FIGURE 3. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE PUMP, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MICROFLUIDIC DEVICE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SINGLE USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MAIL ORDER PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY TRADITIONAL ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 62. CANADA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 63. CANADA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. CANADA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 65. CANADA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 66. CANADA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 67. CANADA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 68. CANADA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. CANADA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 70. CANADA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 71. MEXICO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 72. MEXICO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. MEXICO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 75. MEXICO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 76. MEXICO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 77. MEXICO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. MEXICO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 79. MEXICO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 117. GERMANY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 118. GERMANY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. GERMANY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 120. GERMANY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 121. GERMANY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 122. GERMANY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 123. GERMANY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. GERMANY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 125. GERMANY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 126. FRANCE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 127. FRANCE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. FRANCE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 129. FRANCE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 130. FRANCE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 131. FRANCE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 132. FRANCE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. FRANCE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 134. FRANCE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 144. ITALY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 145. ITALY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. ITALY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 147. ITALY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 148. ITALY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 149. ITALY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 150. ITALY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. ITALY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 152. ITALY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 153. SPAIN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 154. SPAIN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. SPAIN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 156. SPAIN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 157. SPAIN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 158. SPAIN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 159. SPAIN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. SPAIN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 161. SPAIN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 189. DENMARK CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 190. DENMARK CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. DENMARK CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 192. DENMARK CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 193. DENMARK CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 194. DENMARK CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 195. DENMARK CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. DENMARK CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 197. DENMARK CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 207. QATAR CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 208. QATAR CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. QATAR CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 210. QATAR CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 211. QATAR CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 212. QATAR CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 213. QATAR CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. QATAR CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 215. QATAR CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 216. FINLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 217. FINLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. FINLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 219. FINLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 220. FINLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 221. FINLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 222. FINLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. FINLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 224. FINLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 243. EGYPT CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 244. EGYPT CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. EGYPT CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 246. EGYPT CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 247. EGYPT CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 248. EGYPT CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 249. EGYPT CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 250. EGYPT CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 251. EGYPT CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 252. TURKEY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 253. TURKEY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. TURKEY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 255. TURKEY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 256. TURKEY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 257. TURKEY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 258. TURKEY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. TURKEY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 260. TURKEY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 270. NORWAY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 271. NORWAY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. NORWAY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 273. NORWAY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 274. NORWAY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 275. NORWAY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 276. NORWAY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. NORWAY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 278. NORWAY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 279. POLAND

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Cell & Gene Therapy Drug Delivery Devices market report include:
  • Becton, Dickinson and Company
  • Terumo Corporation
  • B. Braun Melsungen AG
  • ICU Medical, Inc.
  • West Pharmaceutical Services, Inc.
  • Gerresheimer AG
  • Ypsomed Holding AG
  • Catalent, Inc.
  • Fresenius SE & Co. KGaA
  • MaxCyte, Inc.

Table Information

Report AttributeDetails
No. of Pages183
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.29 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.08 Billion
Compound Annual Growth Rate10.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Targeted Drug Delivery Device Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Device, Target Organ, Type of Therapy Delivered, Route of Administration, Therapeutic Area, Key Geographical Regions, Leading Players and Sales Forecast - Product Image

Targeted Drug Delivery Device Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Device, Target Organ, Type of Therapy Delivered, Route of Administration, Therapeutic Area, Key Geographical Regions, Leading Players and Sales Forecast

  • Report
  • 275 Pages
  • Global
From
Personalized Nanotechnology for Cell & Gene Therapies Market by Therapy Type, Nanotechnology Type, Application, End User - Global Forecast to 2030 - Product Image

Personalized Nanotechnology for Cell & Gene Therapies Market by Therapy Type, Nanotechnology Type, Application, End User - Global Forecast to 2030

  • Report
  • 187 Pages
  • Global
From
Gene Therapy Market by Vector Type, Treatment Modality, Target Genome, Delivery Mode, Route of Administration, Patient Type, Therapeutic Area, End-User - Global Forecast to 2030 - Product Image

Gene Therapy Market by Vector Type, Treatment Modality, Target Genome, Delivery Mode, Route of Administration, Patient Type, Therapeutic Area, End-User - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Gene Therapy - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Gene Therapy - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Gene Therapy Market Outlook to 2029 - Product Image

Gene Therapy Market Outlook to 2029

  • Report
  • 83 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.